Investors Purchase Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of unusually large options trading on Tuesday. Traders acquired 15,360 call options on the company. This is an increase of approximately 44% compared to the average daily volume of 10,636 call options.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on RXRX shares. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.75.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock opened at $7.26 on Thursday. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $15.74. The business has a 50-day moving average price of $6.91 and a 200 day moving average price of $7.02. The firm has a market cap of $2.84 billion, a PE ratio of -4.75 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the prior year, the firm earned ($0.43) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% on a year-over-year basis. Sell-side analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total value of $76,351.49. Following the completion of the sale, the director now directly owns 7,089,007 shares of the company’s stock, valued at $47,283,676.69. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,341 shares of company stock valued at $393,490 in the last quarter. 15.75% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of RXRX. ARK Investment Management LLC boosted its holdings in Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after buying an additional 4,626,268 shares during the last quarter. State Street Corp raised its position in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after buying an additional 4,120,685 shares during the period. Lingotto Investment Management LLP raised its position in Recursion Pharmaceuticals by 69.0% in the second quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after purchasing an additional 1,500,000 shares during the period. Ghisallo Capital Management LLC purchased a new stake in Recursion Pharmaceuticals in the second quarter valued at approximately $8,250,000. Finally, Perceptive Advisors LLC purchased a new stake in Recursion Pharmaceuticals in the second quarter valued at approximately $5,769,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.